Dublin, March 08, 2018 -- The "Research Antibodies and Reagents Market - Global Opportunity Analysis and Industry Forecast (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
Global research antibodies and reagents market is expected to reach USD 13,276.5 million by 2023, at a CAGR of 6.5% during the forecast period of 2018 to 2023.
Research antibodies and reagents are used concurrently during an experimental research for the development of protein, gene, or antigen specific drugs and biomarkers for rapid detection and diagnosis of chronic diseases.
The report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges in the market dynamics segment. Rising proteomics and genomics research studies, increasing funding for research activities, and growing industry-academia collaborations are majorly driving the global research antibodies and reagents market. However, high cost and time related to development of potential antibodies hinders the growth of this market to some extent.
In addition, the report further gives an extensive outlook on various healthcare facilities served by the research antibodies and reagents. These industries include pharmaceutical and biotechnology industry, academic and research institutes, and contract research organizations.
These end user segments further briefly talks about the trends impacting the growth of these markets and the benefits involved with the use of research antibodies and reagents in these verticals to improve overall efficiency and outcomes of the research experiments for drug discovery and development.
Key questions answered in the report:
- Which are the high growth market segments in terms of product type, technology, applications, end users, and regions/countries?
- What is the historical market for research antibodies and reagents across the globe?
- What are the market forecasts and estimates from the period 2018-2023?
- What was the historical market for research antibodies and reagents?
- What are the major drivers, restraints, opportunities, and challenges in the global research antibodies and reagents market?
- Who are the major players in the global research antibodies and reagents market and what share of the market do they hold?
- Who are the major players in various countries and what share of the market do they hold?
- What are the competitive landscapes and who are the market leaders by sub-region in the global research antibodies and reagents market?
- What are the recent developments in the global research antibodies and reagents market?
- What are the different strategies adopted by the major players in the global research antibodies and reagents market?
- What are the geographical trends and high growth regions/ countries?
- Who are the local emerging players in the global research antibodies and reagents market and how do they compete with the global players?
Key Topics Covered:
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Rising Proteomics and Genomics Research Studies
4.2.1.2. Increase in the Funding for Research Activities
4.2.1.3. Growing Industry-Academia Collaboration
4.2.1.4. Other Drivers
4.2.2. Restraints
4.2.2.1. High Cost and Time Related to Identification and Development of Potential Antibodies
4.2.2.1. Other Restraints
4.2.3. Opportunities
4.2.3.1. Growing Demand for Protein Therapeutics and Personalized Medicines
4.4.3.2. Rising Investment and Focus on Stem-Cell Research
4.4.3.3. Rising Need for New Biomarker Identification
4.2.3.4. Significant Opportunities from Emerging Asia-Pacific and Latin-American Markets
4.4.3.5. Other Opportunities
4.2.4. Challenges
4.2.4.1. Issues Related to Quality and Stability of Research Antibodies
4.2.4.2. Intense Pricing Pressure on Leading Players
4.2.4.3. Other Challenges
4.3. Market Share Analysis, by Key Players
5. Research Antibodies and Reagents Market, by Product
5.1. Introduction
5.2. Reagents
5.2.1. Media and Serum
5.2.2. Stains and Dyes
5.2.3. Probes
5.2.4. Buffers
5.2.5. Solvents
5.2.6. Enzymes
5.2.7. Proteins
5.2.8. Others
5.3. Antibodies
5.3.1. Antibodies Market, by Type
5.3.1.1. Primary Antibodies
5.3.1.2. Secondary Antibodies
5.3.2. Antibodies Market, by Production
5.3.2.1. Monoclonal Antibodies
5.3.2.2. Polyclonal Antibodies
5.3.2.3. Antibody Fragments
5.3.3. Antibodies Market, by Source
5.3.3.1. Mouse
5.3.3.2. Rabbit
5.3.3.3. Others
5.3.4. Antibodies Market, by Research Area
5.3.4.1. Oncology
5.3.4.2. Infectious Diseases
5.3.4.3. Cardiovascular Disease
5.3.4.4. Immunology
5.3.4.5. Neurology
5.3.4.6. Stem Cell
5.3.4.7. Others
6. Research Antibodies and Reagents Market, by Technology
6.1. Introduction
6.2. Western Blotting
6.3. Immunofluorescence
6.4. Immunosorbent Assays
6.5. Flow Cytometry
6.6. Immunohistochemistry
6.7. Immunoprecipitation
6.8. Others
7. Research Antibodies and Reagents Market, by Application
7.1. Introduction
7.2. Proteomics
7.3. Drug Discovery and Development
7.4. Genomics
8. Research Antibodies and Reagents Market, by End Users
8.1. Introduction
8.2. Pharmaceutical & Biotechnology Industry
8.3. Academic & Research Institutes
8.4. Contract Research Organizations
9. Research Antibodies and Reagents Market, by Geography
10. Competitive Landscape
10.1 Introduction
10.2. Approvals
10.3. Partnerships, Agreements, & Collaborations
10.4. Mergers & Acquisitions
10.5. New Product Launches
10.6. Expansions
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
- GE Healthcare (U.S.)
- Merck & Co. Inc.(U.S.)
- Thermo Fisher Scientific Inc.(U.S.)
- Amgen Inc.(U.S.)
- Sanofi (France)
- F. Hoffmann La-Roche Ltd (Switzerland)
- Rockland Immunochemicals Inc.(U.S.)
- Johnson & Johnson (U.S.)
- Agilent Technologies Inc.(U.S.)
- Eli Lilly and Company (U.S.)
- Becton Dickinsonand Company (U.S.)
- Danaher Corporation (U.S.)
- PerkinElmer Inc.(U.S.)
- GenScript Biotech Corporation (U.S.)
- Lonza (Switzerland)
- Bio-Techne Corporation (U.S.)
- Bio-Rad Laboratories Inc.(U.S.)
- Teva Pharmaceutical Industries Limited (Israel)
- Santa Cruz Biotechnology Inc.(U.S.)
- BioLegend Inc.(U.S.)
- Abcam PLC (U.K.)
- Cell Signaling Technology Inc.(U.S.)
For more information about this report visit https://www.researchandmarkets.com/research/mfdgwq/2018_research?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs


Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
OpenAI Restricts Astra AI Over Cyberattack Risks
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 



